Keywords: tarceva, gets, negative, opinion, chmp, swiss, drug

Tarceva gets negative opinion from CHMP

Article | 07 August 2006

Print This

Swiss drug major Roche says that its anticancer agent Tarceva (eriotinib), developed in collaboration with US firm OSI Pharmaceuticals, has ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in